Country
Full text data for US and EP
Status
Type
Filing Date
Publication Date
Inventor
Assignee
Click to expand
IPC
No.
Publication Number
Title
Publication/Patent Number Publication/Patent Number
Publication date Publication date
Application number Application number
Filing date Filing date
Inventor Inventor
Assignee Assignee
IPC IPC
1
US2019121165A1
Publication/Patent Number: US2019121165A1
Publication date: 2019-04-25
Application number: 16/090,986
Filing date: 2017-04-07
Abstract: To provide a translucent member that has the effect of lowering triglycerides, increasing IRS-2, and the like. The above-described problem is solved by a translucent member (1) that blocks or suppresses transmission of at least light that is received by an eye and has a wavelength of 460 nm. The translucent member (1) may be an eyeglass lens or eyeglasses as a whole. The eyeglasses (1) preferably comprise a lens (2) that blocks or suppresses transmission of at least light having a wavelength of 460 nm, and a rim (3) that blocks or suppresses transmission of at least light having a wavelength of 460 nm. The rim (3) preferably comprise a projecting portion (3a) for decreasing a gap between the rim (3) and a face of an eyeglass wearer or eliminating the gap by coming into contact with the face. To provide a translucent member that has the effect of lowering triglycerides, increasing IRS-2, and the like. The above-described problem is solved by a translucent member (1) that blocks or suppresses transmission of at least light that is received by an eye and has a ...more ...less
2
EP3441815A1
Publication/Patent Number: EP3441815A1
Publication date: 2019-02-13
Application number: 17779250.4
Filing date: 2017-04-07
Abstract: To provide a translucent member that has the effect of lowering triglycerides, increasing IRS-2, and the like. The above-described problem is solved by a translucent member (1) that blocks or suppresses transmission of at least light that is received by an eye and has a wavelength of 460 nm. The translucent member (1) may be an eyeglass lens or eyeglasses as a whole. The eyeglasses (1) preferably comprise a lens (2) that blocks or suppresses transmission of at least light having a wavelength of 460 nm, and a rim (3) that blocks or suppresses transmission of at least light having a wavelength of 460 nm. The rim (3) preferably comprise a projecting portion (3a) for decreasing a gap between the rim (3) and a face of an eyeglass wearer or eliminating the gap by coming into contact with the face. To provide a translucent member that has the effect of lowering triglycerides, increasing IRS-2, and the like. The above-described problem is solved by a translucent member (1) that blocks or suppresses transmission of at least light that is received by an eye and has a ...more ...less
3
US2019126075A1
Publication/Patent Number: US2019126075A1
Publication date: 2019-05-02
Application number: 15/764,577
Filing date: 2016-09-30
Abstract: The present invention provides foods and beverages comprising a combination of two or more digestion-resistant components. This invention also provides an agent for producing hydrogen gas in the large intestine, the agent comprising a combination of two or more digestion-resistant components. The foods and beverages or the agent for producing H2 in the large intestine according to this invention can induce sustained production of large amounts of hydrogen gas by intestinal bacteria of more human individuals. The present invention provides foods and beverages comprising a combination of two or more digestion-resistant components. This invention also provides an agent for producing hydrogen gas in the large intestine, the agent comprising a combination of two or more ...more ...less
4
EP3015107B1
Publication/Patent Number: EP3015107B1
Publication date: 2019-08-28
Application number: 14818800.6
Filing date: 2014-06-27
5
US2019129204A1
Publication/Patent Number: US2019129204A1
Publication date: 2019-05-02
Application number: 16/155,097
Filing date: 2018-10-09
Abstract: The purpose of the present invention is to provide a myopia treatment device. A myopia treatment device of the present invention comprises a light transmission part selected from a group consisting of an eyesight correcting tool, an eye protection tool, a face protection tool, a sunshade, a display device, a window, a wall, a light source covering, and a coating material. The light transmission part of the device transmits violet light having a wavelength within a range of 360 nm to 400 nm inclusive and thus treats myopia. Or, the myopia treatment device comprises a light emission part selected from a group consisting of lighting equipment, a display device, and a light irradiation device. The light emission part of the device emits violet light having a wavelength within a range of 360 nm to 400 nm inclusive and thus treats myopia. The purpose of the present invention is to provide a myopia treatment device. A myopia treatment device of the present invention comprises a light transmission part selected from a group consisting of an eyesight correcting tool, an eye protection tool, a face protection tool, a ...more ...less
6
US2019194294A1
Publication/Patent Number: US2019194294A1
Publication date: 2019-06-27
Application number: 16/329,631
Filing date: 2017-09-01
Abstract: The purpose of the present invention is to provide an agent for restoring a visual function or an agent for preventing the deterioration in a visual function, which has an excellent visual function restoring ability. The agent for regenerating a visual function or the agent for preventing the deterioration in a visual function according to the present invention contains, as an active ingredient, a chimeric protein having both an amino acid sequence for a microorganism-origin ion-transporting receptor rhodopsin and an amino acid sequence for an animal-origin G-protein-coupled receptor rhodopsin. The chimeric protein is preferably one in which an amino acid sequence for a cytoplasm-side second loop and/or a cytoplasm-side third loop in the amino acid sequence for the microorganism-origin ion-transporting receptor rhodopsin is substituted by an amino acid sequence for a cytoplasm-side second loop and/or a cytoplasm-side third loop in the G-protein-coupled receptor rhodopsin. The purpose of the present invention is to provide an agent for restoring a visual function or an agent for preventing the deterioration in a visual function, which has an excellent visual function restoring ability. The agent for regenerating a visual function or the agent for ...more ...less
7
EP3508212A1
Publication/Patent Number: EP3508212A1
Publication date: 2019-07-10
Application number: 17846710.6
Filing date: 2017-09-01
Abstract: The purpose of the present invention is to provide an agent for regenerating a visual function or an agent for preventing the deterioration in a visual function, which has an excellent visual function regenerating ability. The agent for regenerating a visual function or the agent for preventing the deterioration in a visual function according to the present invention contains, as an active ingredient, a chimeric protein having both an amino acid sequence for a microorganism-origin ion-translocating receptor rhodopsin and an amino acid sequence for an animal-origin G-protein-conjugated receptor rhodopsin. The chimeric protein is preferably one in which an amino acid sequence for a cytoplasm-side second loop and/or a cytoplasm-side third loop in the amino acid sequence for the microorganism-origin ion-translocating receptor rhodopsin is substituted by an amino acid sequence for a cytoplasm-side second loop and/or a cytoplasm-side third loop in the G-protein-conjugated receptor rhodopsin. The purpose of the present invention is to provide an agent for regenerating a visual function or an agent for preventing the deterioration in a visual function, which has an excellent visual function regenerating ability. The agent for regenerating a visual function or the ...more ...less
8
EP3384881B1
Publication/Patent Number: EP3384881B1
Publication date: 2019-07-03
Application number: 16870821.2
Filing date: 2016-12-02
9
US2019192458A1
Publication/Patent Number: US2019192458A1
Publication date: 2019-06-27
Application number: 16/090,933
Filing date: 2017-04-05
Abstract: Provided are a novel therapeutic or prophylactic agent for graft-versus-host disease, a novel agent for inhibiting fibrocyte infiltration, and a novel agent for inhibiting a decrease in tear secretion and a decrease of goblet cells. A method of treating or preventing graft-versus-host disease comprises administering a phenylbutyric acid or a pharmacologically acceptable salt thereof to a patient in need of treatment or prevention of graft-versus-host disease. It is preferable that the graft-versus-host disease be a graft-versus-host disease that manifests after bone marrow transplantation. It is preferable that the graft-versus-host disease be ocular graft-versus-host disease. Provided are a novel therapeutic or prophylactic agent for graft-versus-host disease, a novel agent for inhibiting fibrocyte infiltration, and a novel agent for inhibiting a decrease in tear secretion and a decrease of goblet cells. A method of treating or preventing ...more ...less
11
WO2018124036A1
Publication/Patent Number: WO2018124036A1
Publication date: 2018-07-05
Application number: 2017046568
Filing date: 2017-12-26
Inventor: Tsubota, Kazuo  
Abstract: [Problem] To provide a display system such as a smartphone, a game machine, a personal computer, or a liquid crystal television, which is provided with a light-emitting element that emits, toward a user, light having a specific wavelength. [Solution] A display system 1 is provided with: a first light-emitting element 6 that emits light used for displaying an image; a second light-emitting element 3 that emits light 7 within the wavelength range of 360-400 nm toward the user; and a control device that controls the emission of the light 7 from the second light-emitting element 3. The second light-emitting element 3 may be a single light-emitting element integrated with the first light-emitting element 6, or may be a light-emitting element provided separately from the first light-emitting element 6. When the second light-emitting element 3 is provided separately from the first light-emitting element 6, the second light-emitting element 3 is preferably provided to the peripheral edge frame 4 of a display screen, is provided within the display screen 2, or is provided as an accessory 5. [Problem] To provide a display system such as a smartphone, a game machine, a personal computer, or a liquid crystal television, which is provided with a light-emitting element that emits, toward a user, light having a specific wavelength. [Solution] A display system 1 is ...more ...less
12
EP2660646A4
Publication/Patent Number: EP2660646A4
Publication date: 2018-01-10
Application number: 11854345
Filing date: 2011-08-10
Assignee: Jin Co., Ltd.
Abstract: Eyewear comprising a frame and a liquid storage portion that is disposed within the frame and that includes a cavity for storing liquid. The liquid storage portion includes a gas passing section that allows gas to pass therethrough from the cavity to an inside surface of the frame Eyewear comprising a frame and a liquid storage portion that is disposed within the frame and that includes a cavity for storing liquid. The liquid storage portion includes a gas passing section that allows gas to pass therethrough from the cavity to an inside surface of the ...more ...less
13
US9968566B2
Publication/Patent Number: US9968566B2
Publication date: 2018-05-15
Application number: 15/506,893
Filing date: 2015-08-26
Abstract: A pharmaceutical composition for prophylaxis and/or treatment of a corneal and conjunctival disease or presbyopia, the composition containing a compound represented by Formula (I), or a salt thereof or a prodrug thereof as an active ingredient, wherein m and n are each independently an integer of 0 to 5; m+n≥1; and each aromatic ring of the compound represented by Formula (I) may be substituted. A pharmaceutical composition for prophylaxis and/or treatment of a corneal and conjunctival disease or presbyopia, the composition containing a compound represented by Formula (I), or a salt thereof or a prodrug thereof as an active ingredient, wherein m and n are each ...more ...less
14
US9877975B2
Publication/Patent Number: US9877975B2
Publication date: 2018-01-30
Application number: 14/901,518
Filing date: 2014-06-27
Abstract: The present invention aims to provide an agent for treating meibomian gland dysfunction. The present invention provides an agent for treating meibomian gland dysfunction, which contains activated vitamin D3 or a derivative thereof as an active ingredient.
15
WO2018030389A1
Publication/Patent Number: WO2018030389A1
Publication date: 2018-02-15
Application number: 2017028727
Filing date: 2017-08-08
Abstract: The present invention provides a food (particularly a supplement, a health supplement, a food for specified health uses, a food having a nutrient function, or a food having function claims) and a preparation for external application (particularly a medicine (a medicine for medical uses, an OTC), a quasi drug, a cosmetic, and a skin care product), each of which contains an NAD-related metabolite or a pharmaceutically acceptable salt or prodrug thereof. The present invention also provides a pharmaceutical composition for preventing or treating an ophthalmic disease selected from the group consisting of presbyopia, glaucoma, diabetic retinopathy, retinitis pigmentosa, age-related macular degeneration, chorioretinal atrophy associated with high myopia, corneal endothelial dystrophy , bullous keratopathy, cataract, retinal artery/vein occlusion, Fuchs's corneal dystrophy, bullous keratopathy, optic neuropathy and Leber's disease. The present invention provides a food (particularly a supplement, a health supplement, a food for specified health uses, a food having a nutrient function, or a food having function claims) and a preparation for external application (particularly a medicine (a medicine for ...more ...less
16
EP3412259A1
Publication/Patent Number: EP3412259A1
Publication date: 2018-12-12
Application number: 17747411.1
Filing date: 2017-01-31
Abstract: A light source for myopia prevention article includes a light emitter to emit light having an emission spectrum continuing from a first wavelength of not less than 360 nm nor more than 400 nm to a second wavelength of more than 400 nm.
17
EP3153139A4
Publication/Patent Number: EP3153139A4
Publication date: 2018-01-17
Application number: 15803562
Filing date: 2015-06-03
Abstract: The purpose of the present invention is to provide a myopia prevention article. The provided myopia prevention article comprises a light transmission part through which ultraviolet light with a wavelength of more than 315 nm and not more than 400 nm or 360 nm to 400 nm inclusive is transmitted and ultraviolet light with a wavelength of 315 nm or less is not transmitted The purpose of the present invention is to provide a myopia prevention article. The provided myopia prevention article comprises a light transmission part through which ultraviolet light with a wavelength of more than 315 nm and not more than 400 nm or 360 nm to 400 nm inclusive ...more ...less
18
US10133092B2
Publication/Patent Number: US10133092B2
Publication date: 2018-11-20
Application number: 15/366,558
Filing date: 2016-12-01
Abstract: The purpose of the present invention is to provide a myopia prevention device. A myopia prevention device of the present invention comprises a light transmission part selected from a group consisting of an eyesight correcting tool, an eye protection tool, a face protection tool, a sunshade, a display device, a window, a wall, a light source covering, and a coating material. The light transmission part of the device transmits light having a wavelength within a range of 350 nm to 400 nm inclusive and thus suppresses the occurrence and progression of myopia. Further, a myopia prevention device comprises a light emission part selected from a group consisting of lighting equipment, a display device, and a light irradiation device. The light emission part of the device emits light having a wavelength within a range of 350 nm to 400 nm inclusive and thus suppresses the occurrence and progression of myopia. The purpose of the present invention is to provide a myopia prevention device. A myopia prevention device of the present invention comprises a light transmission part selected from a group consisting of an eyesight correcting tool, an eye protection tool, a face protection tool ...more ...less
19
US2018351050A1
Publication/Patent Number: US2018351050A1
Publication date: 2018-12-06
Application number: 16/044,909
Filing date: 2018-07-25
Abstract: A light source for myopia prevention article includes a light emitter to emit light having an emission spectrum continuing from a first wavelength of not less than 360 nm nor more than 400 nm to a second wavelength of more than 400 nm.